Drug Profile
CB 201
Alternative Names: CB-201Latest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator Gardedam Therapeutics
- Developer Cantabio Pharmaceuticals
- Class Proteins
- Mechanism of Action Reactive oxygen species modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Type 2 diabetes mellitus
- Discontinued Alzheimer's disease; Parkinson's disease
Most Recent Events
- 29 Aug 2023 Discontinued - Preclinical for Alzheimer's disease in USA (unspecified route)
- 29 Aug 2023 Discontinued - Preclinical for Parkinson's disease in USA (unspecified route)
- 29 Sep 2020 Preclinical trials in Type 2 diabetes mellitus in USA (unspecified route) (Cantabio Pipeline, Sep 2020)